Literature DB >> 14511171

Prophylactic anticoagulation for venous thromboembolic disease in geriatric patients.

Laurie G Jacobs1.   

Abstract

Venous thromboembolic disease (VTED) occurs commonly in geriatric medical patients, causing significant morbidity and mortality. Although VTED is preventable, prophylactic anticoagulation is underused. Awareness of the clinical risk factors that contribute to VTED in the elderly is essential for identifying candidates for prophylaxis. Iatrogenic risk factors include venous catheterization, transvenous pacemaker placement, hormone replacement therapy, and immobilization or prolonged bed rest. Medical conditions associated with increased risk include a previous episode of VTED, myocardial infarction, heart failure, severe lung disease, cancer, and neurological conditions associated with paresis. Obstacles to the widespread usage of VTED prophylaxis in geriatric medical patients include the clinically silent nature of VTED, underestimation of the risk and clinical effect of VTED in this population, and concerns about the cost and safety of anticoagulant therapy in this population. Clinical practice guidelines devised specifically for geriatric medical patients facilitate rational use of thromboprophylaxis in this population. The safety, efficacy, cost-effectiveness, and convenience of low-molecular-weight heparins for thromboprophylaxis are reflected in their increasing prominence in clinical practice guidelines and clinical use.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14511171     DOI: 10.1046/j.1532-5415.2003.51469.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  5 in total

1.  Thromboprophylaxis with the low-molecular-weight heparin bemiparin sodium in elderly medical patients in usual clinical practice: the ANCIANOS study.

Authors:  Leocadio Rodríguez-Mañas; Ricardo Gómez-Huelgas; Fernando Veiga-Fernández; Gema Monteagudo Ruiz; Javier Martínez González
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

Review 2.  Prevention of venous thromboembolism in medically ill patients: a clinical update.

Authors:  Alexander G G Turpie; Alain Leizorovicz
Journal:  Postgrad Med J       Date:  2006-12       Impact factor: 2.401

3.  Probing structural selectivity of synthetic heparin binding to Stabilin protein receptors.

Authors:  Elizabeth H Pempe; Yongmei Xu; Sandhya Gopalakrishnan; Jian Liu; Edward N Harris
Journal:  J Biol Chem       Date:  2012-04-30       Impact factor: 5.157

4.  The human hyaluronan receptor for endocytosis (HARE/Stabilin-2) is a systemic clearance receptor for heparin.

Authors:  Edward N Harris; Janet A Weigel; Paul H Weigel
Journal:  J Biol Chem       Date:  2008-04-22       Impact factor: 5.157

5.  Prophylactic anti-coagulation in cancer palliative care: a prospective randomised study.

Authors:  Catherine Weber; Thierry Merminod; François R Herrmann; Gilbert B Zulian
Journal:  Support Care Cancer       Date:  2007-10-17       Impact factor: 3.603

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.